 By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT We are initiating coverage of Edesa Biotech, Inc. NASDAQ:EDSA with a valuation of 5.00. Edesa is a biopharmaceutical company focused on developing therapies for dermatological and gastrointestinal GI conditions where effective therapies are needed. The companys lead development products are based on inhibition of a family of 